MedTrace Logo

EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions Registry

NCT07625189 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-06-04

No results posted yet for this study

Summary

This is a single-center, investigator-initiated, prospective observational registry that will collect longitudinal clinical data on adult patients (≥18 years) undergoing endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) or microwave ablation (MWA) for pancreatic and other gastrointestinal/hepatobiliary lesions as part of routine clinical care. The registry will not alter standard-of-care management. Data will be abstracted from the medical record and routine clinical systems. Primary outcomes include change in target lesion size on clinically obtained imaging and overall survival following ablation. Secondary outcomes include changes in tumor biomarkers, adverse events, non-target lesion changes, and patient-reported symptoms.

Conditions

  • RFA
  • Microwave Ablation
  • Pancreatic Lesion
  • Gastrointestinal Lesions
  • Ablation Techniques

Sponsors & Collaborators

  • West Virginia University

    lead OTHER

Principal Investigators

  • Shailendra Singh, MD · West Virginia University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-10
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07625189 on ClinicalTrials.gov